Loss of ALK3 Ameliorates Acute but Aggravates Chronic Lung Inflammation In Vivo
Immunology · 2025
DOI: 10.1111/imm.13957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2025. Verfasst von Mathias Hochgerner und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetics and Development of Complex Phenotypes, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life …. Hauptthemen laut MEDLINE: Pneumonia, Bone Morphogenetic Protein Receptors, Type I, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
ALK3 (BMPR1a) is a type‐1 receptor of the TGF‐β receptor superfamily. It translates signals mainly from bone morphogenetic proteins, but also from TGF‐β1. Previously, we showed that specific deletion of ALK3 in antigen‐presenting cells (APCs) led to increased inflammation in the skin. It is unknown whether the regulation of ALK3 in APCs is specific to the skin or generally involved in multiple tissues. Therefore, we investigated the role of ALK3 in APCs in the lung. We used mice with a specific deletion of ALK3 under the CD11c promoter as well as pharmacological blockade of ALK3‐signalling with DMH‐1 in vivo in Bleomycin‐ and LPS‐induced lung inflammation, as well as follow‐up in vitro experiments. Lung inflammation was analysed via histology, flow cytometry and single‐cell‐RNA‐sequencing. Deletion or blockade of ALK3 aggravated Bleomycin‐induced and long‐term LPS‐induced lung inflammation. Interestingly, acute LPS‐induced lung inflammation was ameliorated. ALK3 blockade did not reduce recruitment of immune cells to the lung but changed gene expression in neutrophils, downregulating inflammation‐associated genes. In vitro, DMH‐1 did not directly affect neutrophils but did affect DCs, macrophages and AT‐2 cells. The aggravation of longer‐lasting lung inflammation matches our previous data from the skin, down to reduced numbers of T REG . Unexpectedly, that same loss/blockade of ALK3 ameliorates acute lung inflammation. Our results suggest that ALK3 is an important receptor in APCs, enhancing their ability to activate a fast, neutrophilic inflammation as well as to counteract longer‐lasting inflammations. Thus, ALK3 has (at least) two different functions at different stages of inflammation. With deeper understanding, ALK3 could be an important target for modulating acute and chronic lung inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Genetics and Development of Complex Phenotypes, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Shanghai Key Laboratory of Lung Inflammation and Injury, Zho…
- Ludwig Boltzmann Institute of Lung Vascular Research, Austria.
- State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Institutes of Biomedical Sciences, School of Life Sciences, Inner Mongolia University, Hohhot, China.
- Otto Loewi Research Center, Lung Research Group, Medical University of Graz, Austria.
- The Joint Laboratory for Lung Development and Related Diseases of West China Second University Hospital, Sichuan University and School of Life Sciences of Fudan University, Chengdu, China.
ORCID-Profile: Mathias Hochgerner
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Hochgerner, M., Jiang, Y., Sun, S., Huang, F., Marsh, L. M., Lin, X., & Tang, X. (2025). Loss of ALK3 Ameliorates Acute but Aggravates Chronic Lung Inflammation In Vivo. Immunology. https://doi.org/10.1111/imm.13957
Vancouver
Hochgerner M, Jiang Y, Sun S, Huang F, Marsh LM, Lin X, et al. Loss of ALK3 Ameliorates Acute but Aggravates Chronic Lung Inflammation In Vivo. Immunology. 2025. doi:10.1111/imm.13957
BibTeX
@article{Hochgerner2025,
author = {Hochgerner, Mathias and Jiang, Yamei and Sun, Shenfei and Huang, Fujing and Marsh, Leigh M and Lin, Xinhua and Tang, Xiaofang},
title = {Loss of ALK3 Ameliorates Acute but Aggravates Chronic Lung Inflammation In Vivo},
journal = {Immunology},
year = {2025},
doi = {10.1111/imm.13957}
}
EUVIMED